• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • Ancer®
      • PreVAXâ„¢
    • Lab Services
      • HLA Binding Assay
      • T Cell Assay
      • Innate Assay
    • Consulting Services
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
EpiVax worked for 21 years to be able to make a vaccine in 24 hours!

EpiVax worked for 21 years to be able to make a vaccine in 24 hours!

by Adam | Feb 10, 2020 | News

COVID-19 Coverage EpiVax is dedicated to providing continuously updated information concerning COVID-19 vaccine efforts. For all updates, press releases, interviews and more please visit our official COVID-19 page. Click here UPDATE March 16, 2020:   As closures and...
European Immunogenicity Platform Symposium: Lisbon, Portugal February 17-19, 2020

European Immunogenicity Platform Symposium: Lisbon, Portugal February 17-19, 2020

by Annie De Groot | Feb 3, 2020 | Events

Dr. Anne De Groot will be going to Lisbon, Portugal to attend the European Immunogenicity Platform Symposium from 17-19th Feb.  While there, she will be giving a talk on EpiVax’s immunoinformatics platform on Day 2, 18Feb at 2:30PM.  The talk will focus on...

Recent Posts

  • EpiVax Supports Life-Saving Programs Through Partnerships with GAIA Vaccine Foundation and Clínica Esperanza/Hope Clinic
  • EpiVax and FDA Scientists Publish New Insights on Immunogenicity Risks of Peptide-Related Impurities in Generic Teriparatide
  • Doing Well and Giving Back in December
  • The Power of Tregs: From Sakaguchi’s Nobel Discovery to EpiVax Innovation
  • The Tregs as Medicine Symposium | Advances in Tolerance Research

Recent Comments

No comments to show.

Join our newsletter

Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CMO, Dr. Annie De Groot.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.